Drug facts
MoleculeBimatoprost (Lumigan)
Generics already compete: 9 makers on the market. 11 A-rated products from 9 makers substitute at the counter.
Lumigan was first approved by the FDA on 03/16/2001 under NDA 021275; the application holder is Abbvie Inc. The Orange Book lists NDA 021275 as discontinued.
The latest NADAC for BIMATOPROST 0.03% EYE DROPS is $6.57 per mL (as of 10/28/2026).
Holder Abbvie IncApplication NDA 021275Approved 03/16/2001
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No NDA 021275 patent listed in the Orange Book Orange Book
- Later patents, other products
- Zolymbus 06/08/2036; Durysta 10/31/2034; Lumigan (NDA 022184) 06/13/2027 Orange Book
02Competition
- Generics
- 9 generic makers Orange Book
- First generic approved
- 12/01/2014 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Bimatoprost profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $6.57 per mLBIMATOPROST 0.03% EYE DROPS, as of 10/28/2026 CMS NADAC
- Latest recall
- 03/31/2025Class II, Bimatoprost Powder, Medisca Inc. FDA enforcement
04Product
- Application holder
- Abbvie Inc Orange Book
- Application
- NDA 021275 Orange Book
- First approved
- 03/16/2001 Orange Book
- Dosage forms
- gel; implant; solution/drops
- Routes
- ophthalmic, topical
- Other brand names
- DurystaLatisseZolymbus
- Status
- NDA 021275 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.